1-[4-[4-(4-甲氧基苯基)-1-哌嗪基]苯基]-3-(1-甲基乙基)-2-咪唑烷酮 | 95182-50-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 1-[4-[4-(4-甲氧基苯基)-1-哌嗪基]苯基]-3-(1-甲基乙基)-2-咪唑烷酮
• 英文名称: 1-[4-[4-(4-methoxyphenyl)-1-piperazinyl]phenyl]-3-(1-methylethyl)-2-oxoimidazolidine
• 英文别名: 1-[4-[4-(4-methoxyphenyl)-1-piperazinyl]phenyl]-3-(1-methylethyl)-2-imidazolidinone；1-[4-[4-(4-methoxyphenyl)piperazin-1-yl]phenyl]-3-propan-2-ylimidazolidin-2-one
• CAS: 95182-50-6
• 化学式: C₂₃H₃₀N₄O₂
• 分子量: 394.517
• InChiKey: KMIIRMKLQKPOAL-UHFFFAOYSA-N

物化性质

• 熔点：
  234.5 °C
• 沸点：
  571.0±60.0 °C(Predicted)
• 密度：
  1.177

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  39.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-[4-[4-(4-甲氧基苯基)-1-哌嗪基]苯基]-3-(1-甲基乙基)-2-咪唑烷酮 在 sodium hydroxide 、 氢溴酸 、 sodium hydrogensulfite 作用下， 以 溶剂黄146 、 N,N-二甲基甲酰胺 为溶剂， 反应 26.0h， 生成 1-[4-[4-[4-[[(2S,4R)-2-(2,4-difluorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-3-propan-2-ylimidazolidin-2-one
  参考文献：
  名称：

  Synthesis and in Vitro and in Vivo Structure−Activity Relationships of Novel Antifungal Triazoles for Dermatology

  摘要：

  In search for new compounds with potential for clinical use as antifungal agents in dermatology, a series of 12 azole compounds were synthesized stereospecifically and investigated specifically for their activity against dermatophyte fungal infections in animal models. This panel of azoles was studied in vitro and compared with itraconazole and terbinafine for their antifungal activity using a panel of 24 Candida spp. and 182 dermatophyte isolates. Three azoles (1c, 2c, and 4c) showed in vitro antifungal potency equivalent to itraconazole, but superior to terbinafine, against a panel of 24 Candida spp. with comparable or lower activity than that of itraconazole and terbinafine against 182 dermatophyte isolates and only rare activity against other pathogenic fungi. However, in vivo 1c and 4c, both given orally, demonstrated antifungal activity at least three times greater than itraconazole and were superior compared to terbinafine in M. cants infected guinea pigs. In a mouse model infected by T mentagrophytes, again 4c, but not 1c, showed 5-fold superior activity over itraconazole and terbinafine. Compound 2c was effective in both models but less effective than itraconazole in these models. On the basis of these promising results, 4c is currently being clinically investigated for its potential as a novel antifungal agent against dermatophytosis.

  DOI：

  10.1021/jm0494772
• 作为产物：
  描述：

  1-(4-氨基苯基)-4-(4-甲氧基苯基)哌嗪 在 palladium on activated charcoal 4-二甲氨基吡啶 、 甲酸 、 氢气 、 溶剂黄146 、 三乙胺 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 9.0h， 生成 1-[4-[4-(4-甲氧基苯基)-1-哌嗪基]苯基]-3-(1-甲基乙基)-2-咪唑烷酮
  参考文献：
  名称：

  Synthesis and in Vitro and in Vivo Structure−Activity Relationships of Novel Antifungal Triazoles for Dermatology

  摘要：

  In search for new compounds with potential for clinical use as antifungal agents in dermatology, a series of 12 azole compounds were synthesized stereospecifically and investigated specifically for their activity against dermatophyte fungal infections in animal models. This panel of azoles was studied in vitro and compared with itraconazole and terbinafine for their antifungal activity using a panel of 24 Candida spp. and 182 dermatophyte isolates. Three azoles (1c, 2c, and 4c) showed in vitro antifungal potency equivalent to itraconazole, but superior to terbinafine, against a panel of 24 Candida spp. with comparable or lower activity than that of itraconazole and terbinafine against 182 dermatophyte isolates and only rare activity against other pathogenic fungi. However, in vivo 1c and 4c, both given orally, demonstrated antifungal activity at least three times greater than itraconazole and were superior compared to terbinafine in M. cants infected guinea pigs. In a mouse model infected by T mentagrophytes, again 4c, but not 1c, showed 5-fold superior activity over itraconazole and terbinafine. Compound 2c was effective in both models but less effective than itraconazole in these models. On the basis of these promising results, 4c is currently being clinically investigated for its potential as a novel antifungal agent against dermatophytosis.

  DOI：

  10.1021/jm0494772

文献信息

• Method for Manufacture of 2-Oxoimidazolidines
  申请人：Peterson John R.

  公开号：US20100222588A1

  公开（公告）日：2010-09-02

  There is provided a method for manufacture of 2-oxoimidazolidines of Formula I comprising one or more of the steps of converting an amine to an acylation agent, condensation of the acylation agent with a bi-functional compound of structure L-C(R 4 )(R 5 )—C(R 2 )(R 3 )—NHR 1 , wherein L is a leaving group, and ring closure of the resulting urea. In this manner, certain 2-oxoimidazolidines may be manufactured that are useful intermediates for the production of Pramiconazole and structurally related compounds.

  提供了一种制备式I的2-氧代咪唑啉的方法，包括以下一项或多项步骤：将胺转化为酰化剂，将酰化剂与结构为L-C(R4)(R5)—C(R2)(R3)—NHR1的双功能化合物缩合，其中L是一个离去基团，并闭环生成的脲。通过这种方式，可以制备出一些对于生产Pramiconazole和结构相关化合物有用的2-氧代咪唑啉中间体。
• Method for manufacture of 2-oxoimidazolidines
  申请人：Peterson John R.

  公开号：US08431699B2

  公开（公告）日：2013-04-30

  There is provided a method for manufacture of 2-oxoimidazolidines of Formula I comprising one or more of the steps of converting an amine to an acylation agent, condensation of the acylation agent with a bi-functional compound of structure L-C(R4)(R5)—C(R2)(R3)—NHR1, wherein L is a leaving group, and ring closure of the resulting urea. In this manner, certain 2-oxoimidazolidines may be manufactured that are useful intermediates for the production of Pramiconazole and structurally related compounds.

  提供了一种制备式I的2-氧代咪唑啉的方法，包括将胺转化为酰化试剂的一步或多步，将酰化试剂与具有结构L-C（R4）（R5）-C（R2）（R3）-NHR1的双官能化合物缩合，其中L是离去基团，以及环闭合所得尿素。通过这种方法，可以制备出某些有用的2-氧代咪唑啉中间体，用于生产Pramiconazole和结构相关的化合物。
• METHOD FOR MANUFACTURE OF 2-OXOIMIDAZOLIDINES
  申请人：Peterson John R.

  公开号：US20130237705A1

  公开（公告）日：2013-09-12

  A method for the manufacture of 2-oxoimidazolidines comprising the steps of converting an isocyanate and an amine to a urea, and then performing a ring closure of the urea to yield the 2-oxoimidazolidine is disclosed. The 2-oxoimidazolidines produced may then be used in the production of Pramiconazole and other structurally related compounds.

  公开了一种制造2-氧代咪唑啉的方法，包括将异氰酸酯和胺转化为尿素，然后进行环闭合反应以产生2-氧代咪唑啉。所生产的2-氧代咪唑啉可以用于生产Pramiconazole和其他结构相关的化合物。
• ((4-(4-(4-Phenyl-1-piperazinyl)phenoxymethyl)-1,3-dioxolan-2-yl)methyl)-1H-imidazoles and 1H-1,2,4-triazoles
  申请人：JANSSEN PHARMACEUTICA N.V.

  公开号：EP0118138B1

  公开（公告）日：1989-06-14
• HEERES, JAN;STOKBROOKX, RAYMOND A.;BACKX, LEO J. J.
  作者：HEERES, JAN、STOKBROOKX, RAYMOND A.、BACKX, LEO J. J.

  DOI：——

  日期：——